Premium
Synthesis of sophocarpine triflorohydrazone and its proliferation inhibition and apoptosis induction activity in myeloma cells through Notch3‐p53 signaling activation
Author(s) -
Wang Yong,
Li Wen,
Huang Fangmei,
Wu Xiaojian,
Chen Wenbin,
Dong Ming,
Zhou Jie
Publication year - 2021
Publication title -
environmental toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 77
eISSN - 1522-7278
pISSN - 1520-4081
DOI - 10.1002/tox.23053
Subject(s) - apoptosis , viability assay , microbiology and biotechnology , flow cytometry , chemistry , cell growth , multiple myeloma , bone marrow , cancer research , mtt assay , hes1 , signal transduction , cell , biology , immunology , notch signaling pathway , biochemistry
Multiple myeloma is indicated by the presence of excessive monoclonal plasma cells in bone marrow, which result in the formation of osteolytic lesions. The present study investigated SCA as anti‐proliferative agent for myeloma cells and explored the mechanism associated. Effect of SCA on viabilities of KRASA12 and AMO‐1 cells was evaluated by MTT assay and apoptotic ratio using flow cytometry. Protein expression was investigated by western blotting and expression of genes related to Notch3‐p53 signaling axis using RT‐PCR assay. Increase in SCA concentration caused a significant ( P < .01) reduction in KRASA12 and AMO‐1 cell viability. The KRASA12 and AMO‐1 cell viabilities were reduced to 29% and 21%, respectively on treatment with 21 μM doses of SCA. SCA treatment of KRASA12 and AMO‐1 cells significantly ( P < .05) increased apoptosis compared with untreated cells. The Bcl‐2 (26 kDa) protein expression was reduced whereas the Bax (21 kDa) and cleaved caspase‐3 levels elevated in SCA treated KRASA12 and AMO‐1 cells. Treatment with SCA significantly promoted Hes1, p53 (53 kDa) and Hey1 mRNA expression in KRASA12 and AMO‐1 cells. Treatment of KRASA12 and AMO‐1 cells with SCA led to a marked reduction in Notch3 protein expression. SCA inhibits KRASA12 and AMO‐1 myeloma cell proliferation by promoting pro‐apoptotic proteins. Moreover, SCA treatment suppressed Hes1 and Hey1 mRNA expression and targeted Notch3 expression. Therefore, SCA may be studied further for development of treatment for myeloma.